Eine Sicherheits- und Wirksamkeitsstudie von Nivolumab in Kombination mit Ipilimumab zur Behandlung von nicht-kleinzelligem Lungenkarzinom (NSCLC)

Drug: Nivolumab in combination with Ipilimumab

Inclusion Criteria:

- Histologically confirmed Stage 4 or recurrent non-small cell lung cancer

- Eastern Cooperative Oncology Group (ECOG) score 0-1 (Physically able to carry out
light housework or office work through to being fully active as you were before
cancer)

- No prior systemic anticancer therapy (including EGFR and ALK inhibitors)

- Tissue or Programmed death-ligand 1 (PD-L1) results available

Cohort 1A Inclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) score 2 or

- Eastern Cooperative Oncology Group (ECOG) score 0-1 and one disease specific criteria
as listed in the protocol

Cohort C Inclusion Criteria:

- High Tumor Mutation Burden

Exclusion Criteria:

- Untreated brain metastases

- An active malignancy that requires concurrent intervention

- Active, known or suspected autoimmune disease

- Carcinomatous meningitis, which means there is inflammation of the covering of the
brain, caused by cancer

Other protocol-defined inclusion/exclusion criteria apply